Catalent (CTLT) Lowers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing
May 19, 2023 7:00 AM EDTSOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (Catalent or the Company) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Companys Notification of Late Filing on Form 12b-25 filed on May 11, 2023 (the Form 12b-25) with the Securities and Exchange Commission (the SEC); the Companys ongoing focus on finalizing its financial statements and other disclosures in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the Form 10-Q); and completing its quarterly closing processes and... More
